Fractyl Health (GUTS) Change in Receivables (2023 - 2024)
Fractyl Health's (GUTS) quarterly Change in Receivables came in at -$7000.0 in Q1 2024, down 240.0% YoY from $5000.0 in Q2 2023, and down 250.0% on a QoQ basis from -$2000.0 in Q4 2023.
Fractyl Health (GUTS) Change in Receivables (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of Change in Receivables data on file, last reported at -$7000.0 in Q1 2024.
- Quarterly Change in Receivables fell 240.0% year-over-year to -$7000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$41000.0 (down 286.36% YoY) and the FY2024 annual result came in at -$22000.0, down 200.0% from the prior year.
- Change in Receivables eased to -$7000.0 in Q1 2024, from -$2000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $51000.0 in Q2 2023 to a low of -$32000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | -32,000.00 |
| Sep 30, 2023 | -32,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Mar 31, 2023 | 5,000.00 |